Aptevo Therapeutics (APVO) Non-Current Deffered Revenue (2015 - 2017)

Aptevo Therapeutics has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $2.8 million in Q2 2017.

• Quarterly Non-Current Deffered Revenue fell 16.29% year-over-year to $2.8 million in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $2.8 million (down 16.29% YoY) and the FY2016 annual result came in at $2.9 million, down 12.72% from the prior year.
• Non-Current Deffered Revenue was little changed at $2.8 million in Q2 2017 per APVO's latest filing, from $2.8 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $3.3 million in Q2 2016 and troughed at $2.8 million in Q2 2017.
• A 3-year average of $3.0 million and a median of $3.0 million in 2016 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2016 and 2017: Non-Current Deffered Revenue declined 12.72% in 2016, then fell 16.29% in 2017.
• Over 3 years, Non-Current Deffered Revenue stood at $3.3 million in 2015, then fell by 12.72% to $2.9 million in 2016, then slipped by 3.45% to $2.8 million in 2017.
• According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.8 million, $2.8 million, and $2.9 million for Q2 2017, Q1 2017, and Q4 2016 respectively.